2nd Annual Gabelli Funds - Columbia Business School Healthcare Symposium - Friday, November 13, 2020

Join us as we discuss today's pressing healthcare issues.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005244/en/

Bunny Ellerin, Director, HPM, Columbia Business School, MBA, Harvard Business School, BA, Columbia University (Photo: Business Wire)

Bunny Ellerin, Director, HPM, Columbia Business School, MBA, Harvard Business School, BA, Columbia University (Photo: Business Wire)

CO-HOSTS:

Bunny Ellerin

Director, HPM, Columbia Business School

Jing He

Biotech Analyst, Gabelli Funds

  • MBA, Harvard Business School
  • BA, Columbia University
  • MBA, Columbia Business School
  • MA, Washington University in St. Louis
  • BS, Peking University

Time

Agenda

9:00 – 9:10 AM

Welcome

  • Bunny Ellerin, Director, Healthcare and Pharmaceutical Management Program

9:10 – 10:00 AM

Vaccines & Therapeutics to Treat COVID-19

  • David Hering, Regional President, North America, Pfizer Vaccines
  • Dr. Robert Paris, Vice President, Infectious Diseases, Moderna
  • Dr. David Weinreich, Senior Vice President, Global Clinical Development, Regeneron
  • (Moderator) Jing He ‘15, Biotech Analyst, Gabelli Funds

10:10 – 11:00 AM

Health Policy & Reimbursement Trends

  • Dr. Deepa Kumaraiah, Senior Vice President, Service Lines and Chief Physician, NYP Medical Groups, NewYork-Presbyterian
  • Melissa Schulman, Senior Vice President of Government Affairs, CVS Health
  • Professor Michael Sparer, Chair, Health Policy and Management, Columbia University Mailman School of Public Health
  • (Moderator) Jeff Jonas, Portfolio Manager, Gabelli Funds

11:10 – Noon

Healthcare Delivery in a Virtual World

  • Dr. Amy Fahrenkopf, President, HSS Health and Senior Vice President, Hospital for Special Surgery
  • Jason Gorevic, CEO, Teladoc Health
  • Dr. Julie Silverstein, Divisional President, Oak Street Health
  • (Moderator) Kevin Kedra, Healthcare Analyst, G.research

Click Here to Register

Gabelli Funds, LLC is a registered investment adviser with the Securities and Exchange Commission and is a wholly owned subsidiary of GAMCO Investors, Inc. (NYSE: GBL).

Douglas R. Jamieson
914-921-5020
djamieson@gabelli.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)
SVN-114 selected as the lead candidate for PTSD discovery programme

SVN-114 selected as the lead candidate for PTSD discovery programme

Novel compound from patent-pending SVN-SDN-14 series targeting a major global mental health disorder

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces the selection of SVN-114 as the lead candidate from the Company's proprietary SVN-SDN-14 discovery... Keep Reading...
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused... Keep Reading...
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly owned... Keep Reading...
Box of Moderna COVID-19 vaccine vials with red caps and labels.

Moderna to Pay US$950 Million to Settle COVID-19 Vaccine Patent Dispute

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine.The pharmaceuticals giant announced it has reached a global settlement with Arbutus Biopharma (NASDAQ:ABUS) and Genevant Sciences GmbH over claims... Keep Reading...
Scientists examining a sample under a microscope in a lab setting.

Gilead to Acquire Arcellx in US$7.8 Billion Bet on Cancer Therapy

Gilead Sciences (NASDAQ:GILD) announced plans to acquire cancer immunotherapy partner Arcellx (NASDAQ:ACLX) in a deal worth up to US$7.8 billion, moving to take full control of their jointly developed multiple myeloma therapy anito-cel as it seeks to expand its oncology pipeline.The agreement,... Keep Reading...
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its second quarter of... Keep Reading...

Interactive Chart

Latest Press Releases

Related News